Transperineal Targeted Microwave Ablation (TMA) of localized prostate cancer guided by MRI-Ultrasound fusion and organ-based tracking: a pilot study.

[1]  M. Sibony,et al.  Feasibility and safety of targeted focal microwave ablation of the index tumor in patients with low to intermediate risk prostate cancer: Results of the FOSTINE trial , 2021, PloS one.

[2]  R. V. D. van den Bergh,et al.  Focal Therapy for Prostate Cancer: Complications and Their Treatment , 2021, Frontiers in Surgery.

[3]  J. Lagendijk,et al.  Conventional radical versus focal treatment for localised prostate cancer: a propensity score weighted comparison of 6-year tumour control , 2021, Prostate Cancer and Prostatic Diseases.

[4]  Antonio P. DeRosa,et al.  A systematic review of outcomes after thermal and nonthermal partial prostate ablation , 2021, Prostate international.

[5]  C. Ogden,et al.  Focal therapy compared to radical prostatectomy for non-metastatic prostate cancer: a propensity score-matched study , 2020, Prostate cancer and prostatic diseases.

[6]  H. G. van der Poel,et al.  EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. , 2020, European urology.

[7]  C. Ng,et al.  Transperineal microwave ablation of prostate cancer guided by MRI ultrasound fusion and organ based tracking technology , 2020 .

[8]  F. Montorsi,et al.  Medium‐term oncological outcomes in a large cohort of men treated with either focal or hemi‐ablation using high‐intensity focused ultrasonography for primary localized prostate cancer , 2019, BJU international.

[9]  Raj Persad,et al.  A Multicentre Study of 5-year Outcomes Following Focal Therapy in Treating Clinically Significant Nonmetastatic Prostate Cancer , 2018, European urology.

[10]  P. Stricker,et al.  Focal irreversible electroporation as primary treatment for localized prostate cancer , 2018, BJU international.

[11]  David Gillatt,et al.  10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer. , 2017, The New England journal of medicine.

[12]  M. Roobol,et al.  A Decade of Active Surveillance in the PRIAS Study: An Update and Evaluation of the Criteria Used to Recommend a Switch to Active Treatment. , 2016, European urology.

[13]  Leonard Marks,et al.  Final Results of a Phase I/II Multicenter Trial of WST11 Vascular Targeted Photodynamic Therapy for Hemi-Ablation of the Prostate in Men with Unilateral Low Risk Prostate Cancer Performed in the United States. , 2016, The Journal of urology.

[14]  C. Stief.  Final Results of a Phase I/II Multicenter Trial of WST11 Vascular Targeted Photodynamic Therapy for Hemi-Ablation of the Prostate in Men with Unilateral Low Risk Prostate Cancer Performed in the United States , 2016 .

[15]  E. Barret,et al.  Focal cryoablation: a treatment option for unilateral low‐risk prostate cancer , 2014, BJU international.

[16]  Monish Aron,et al.  3-Dimensional elastic registration system of prostate biopsy location by real-time 3-dimensional transrectal ultrasound guidance with magnetic resonance/transrectal ultrasound image fusion. , 2012, The Journal of urology.